

expertise and fairly balanced membership: Members selected will represent a wide variety of interests, including consumers, individuals with disabilities, community and/or other non-profit or governmental organizations, regulators, and industry or, if serving as Special Government Employees in their personal capacity, will have significant expertise in the issues to be addressed by the Committee.

Members will represent a wide variety of entities with interests in consumer or disability access issues within the Federal Communications Commission's purview, including: consumer or community organizations, which may include people who are blind or visually impaired, people who are deaf or hard of hearing, people with cognitive disabilities, people with multiple disabilities, including those who are deafblind, and people who have speech disabilities; state, local, or tribal governments; and companies or trade associations in various sectors of the communications industry. Members may also include consumers serving on their own behalf or individuals who have significant expertise regarding the issues to be addressed by the committee, who may serve as Special Government Employees. Together, these members will represent a balance of viewpoints necessary to address effectively the issues to be considered by the committee.

4. *List of all other Federal advisory committees of the agency:* In addition to the CPAAC, the FCC has three discretionary FACA committees:

- (a) Communications Security, Reliability and Interoperability Council
- (b) Technological Advisory Council
- (c) World Radiocommunication Conference Advisory Committee

5. Justification that the information or advice provided by the Federal advisory committee or subcommittee is not available from another Federal advisory committee, another Federal Government source, or any other more cost-effective and less burdensome source.

The FCC must stay apprised of existing and emerging issues in telecommunications and video programming which may affect consumers, including individuals with disabilities, and take action to benefit the American public and ensure compliance with the Communications Act of 1934, as amended. The FCC must exercise many tools, including by relying on federal advisory committees, to keep pace with opportunities and challenges posed by new and emerging

communications technologies. The members of the committee bring outside knowledge and expertise from the perspectives of industry, trade associations, and organizations representing consumers and individuals with disabilities, which will inform agency staff to accomplish our mission.

6. *If the consultation is a committee renewal, a summary of the previous accomplishments of the committee and the reasons it needs to continue:* Recommendations from past terms of the advisory committee have informed the Commission's work in addressing consumer and disability issues. For example, past recommendations have led to Commission actions that empowered consumers and advanced important consumer protection priorities. Numerous recommendations have informed the Commission's work to combat robocalls, including the use of SHAKEN/STIR and call blocking rules. Recommendations have also focused on advancements in communications technology, mobile device security, changes to FCC consumer complaint intake and reporting, as well as consumer education campaigns for the Digital TV transition. Other recommendations on the Use of Telecommunication Relay Services on Video Conferencing Platforms expedited the deployment of relay on platforms like Zoom and Teams. Another set of recommendations on the Use of Artificial Intelligence to Caption Live Video Programming will help inform future efforts to modernize captioning regulations. And recommendations on Direct Video Calling (DVC) led to a DVC Forum that we hosted at the FCC.

The FCC's top priorities are aligned with the Communications Act of 1934, as amended by Congress, which requires the FCC to protect consumers and ensure accessibility of telecommunications and video programming. The FCC needs to understand how existing and emerging issues in these fields affect consumers, including people with disabilities, to ensure that it adopts regulations such that telecommunications and video programming continue to benefit the American public, by engaging with the stakeholders most affected by these issues, including through federal advisory committee engagement.

7. *Explanation of why the committee/subcommittee is essential to the conduct of agency business:* The Consumer Protection and Accessibility Advisory Committee is chartered to focus on key issues that are essential to the FCC's business, including issues affecting consumer protection and education; implementation of statutes, Commission

rules, and policies to protect consumers; promoting consumer participation and input into Commission rulemaking proceedings and other decision-making processes; impact of new and emerging communications technologies on consumers, including those in underserved areas; communications access for people with disabilities, and video programming access for people with disabilities. Telecommunications and video programming are continually evolving, with opportunities and challenges affecting consumers—including people with disabilities. Continual input and engagement through the Consumer Protection and Accessibility Advisory Committee is essential to ensure that the FCC has the data and tools necessary to address these opportunities and challenges affecting consumers.

Dated: September 25, 2026.

Federal Communications Commission.

Robert Garza,

Legal Advisor, Consumer and Governmental Affairs Bureau.

[FR Doc. 2026-20005 Filed 9-29-26; 8:45 am]

BILLING CODE 6712-01-P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to remove personal or business

information including confidential, contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Benjamin W. McDonough, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than October 15, 2026.

A. Federal Reserve Bank of Minneapolis (Mark Nagle, Assistant Vice President) 90 Hennepin Avenue, Minneapolis, Minnesota 55480-0291. Comments can also be sent electronically to MA@mpls.frb.org:

1. *Michael Johnson, Litchfield, Minnesota*, to acquire voting shares of Darwin Bancshares, Inc. ("Company"), and thereby indirectly acquire voting shares of Perennial Bank ("Bank"), both of Darwin, Minnesota.

In addition, *Jeb Johnson, New London, Minnesota; Max Johnson, Bryce Johnson, and Josh Johnson, all of Darwin, Minnesota; Zachary Johnson, Grove City, Minnesota; Chad Johnson, Monticello, Minnesota; Rachael Larson, St. Cloud, Minnesota; and Krysta Roemeling, Avon, Minnesota*; to join the Johnson Family Control Group, a group acting in concert, to retain voting shares of Company, and thereby indirectly retain voting shares of Bank.

Board of Governors of the Federal Reserve System.

Michele Taylor Fennell,

Associate Secretary of the Board.

[FR Doc. 2026-20017 Filed 9-29-26; 8:45 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2026-P-4574]

Determination That ISTURISA (Osilodrostat) Tablets, 10 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) has determined that ISTURISA (osilodrostat) tablets, 10 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to

approve abbreviated new drug applications (ANDAs) for osilodrostat tablets, 10 mg if all other legal and regulatory requirements are met.

FOR FURTHER INFORMATION CONTACT:

Heather Dorsey, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6269, Silver Spring, MD 20993-0002, 301-796-3600, heather.dorsey@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j)) allows the submission of an ANDA to market a generic version of a previously approved drug product. To obtain approval, the ANDA applicant must show, among other things, that the generic drug product: (1) has the same active ingredient(s), dosage form, route of administration, strength, conditions of use, and (with certain exceptions) labeling as the listed drug, which is a version of the drug that was previously approved, and (2) is bioequivalent to the listed drug. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA).

Section 505(j)(7) of the FD&C Act requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the "Approved Drug Products With Therapeutic Equivalence Evaluations," which is known generally as the "Orange Book." Under FDA regulations, drugs are removed from the list if the Agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).

A person may petition the Agency to determine, or the Agency may determine on its own initiative, whether a listed drug was withdrawn from sale for reasons of safety or effectiveness. This determination may be made at any time after the drug has been withdrawn from sale, but must be made prior to approving an ANDA that refers to the listed drug (§ 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that does not refer to a listed drug.

ISTURISA (osilodrostat) tablets, 10 mg, is the subject of NDA 212801, held by Recordati Rare Diseases, Inc., and initially approved on March 6, 2020. ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

ISTURISA (osilodrostat) tablets, 10 mg, is currently listed in the "Discontinued Drug Product List" section of the Orange Book.

Annora Pharma Private Limited submitted a citizen petition dated April 24, 2026 (Docket No. FDA-2026-P-4574), under 21 CFR 10.30, requesting that the Agency determine whether ISTURISA (osilodrostat) tablets, 10 mg, was withdrawn from sale for reasons of safety or effectiveness.

After considering the citizen petition and reviewing Agency records and based on the information we have at this time, FDA has determined under § 314.161 that ISTURISA (osilodrostat) tablets, 10 mg, was not withdrawn for reasons of safety or effectiveness. The petitioner has identified no data or other information suggesting that ISTURISA (osilodrostat) tablets, 10 mg, was withdrawn for reasons of safety or effectiveness. We have carefully reviewed our files for records concerning the withdrawal of ISTURISA (osilodrostat) tablets, 10 mg, from sale. We have also independently evaluated relevant literature and data for possible postmarketing adverse events. We have found no information that would indicate that this drug product was withdrawn from sale for reasons of safety or effectiveness.

Accordingly, the Agency will continue to list ISTURISA (osilodrostat) tablets, 10 mg, in the "Discontinued Drug Product List" section of the Orange Book. The "Discontinued Drug Product List" delineates, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. ANDAs that refer to ISTURISA (osilodrostat) tablets, 10 mg, may be approved by the Agency as long as they meet all other legal and regulatory requirements for the approval of ANDAs. If FDA determines that labeling for this drug product should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026-19968 Filed 9-29-26; 8:45 am]

BILLING CODE 4164-01-P